The randomized phase III TRAP2-trial is expected to start recruiting in the Netherlands shortly, a trial that will hopefully lead to more robust evidence for the effectiveness of anti-HER2 therapies in the treatment of esophageal cancer. This evidence concerns the gene ERBB2 and esophageal cancer.